Bionova plans to construct a new state-of-the-art biologics manufacturing facility.
The new GMP biologics manufacturing center is constructed with an area covering 36,000 sq. ft. This new biomanufacturing site will make use of single-use technologies for all core unit operations consisting of two 2,000-liter mammalian cell culture trains, capable of producing multiple monoclonal antibodies and other recombinant proteins in larger quantities.
The new plant will advance the multi-product manufacturing of monoclonal antibodies and other recombinant proteins. In addition, this expansion will also generate more than 50 new jobs to bolster GMP production.
The construction of the manufacturing facility is expected to be completed in 10 months and start its operations by Q3 2021.